Other languages HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Market Closed - London S.E. Other stock markets 11:35:09 2024-04-26 EDT			5-day change	1st Jan Change
290 ^GBX	-4.61%		+7.41%	+2.47%

04-26	EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	MT
04-26	Hutchmed notes CHMP's positive opinion for fruiquintinib approval	AN

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hutchmed notes CHMP's positive opinion for fruiquintinib approval	04-26
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer	04-26
Hutchmed to Present New Data at US Cancer Research Conference	04-05
HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024	04-05
Hutchmed endometrial cancer treatment application accepted for review	04-02
HSBC in special payout on Canada sale; Astra FDA win	04-02
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	04-02
Sector Update: Health Care Stocks Advance Premarket Thursday	03-28
Hutchmed lung cancer treatment accepted for review in China	03-28
JD Sports backs outlook; Spirent accepts new offer	03-28
Hutchmed (China)'s NDA Application Accepted by Chinese Authorities	03-28
HUTCHMED Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC	03-27
Hutchmed begins registration stage for sovleplenib phase 2/3 trial	03-22
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug	03-22
Hutchmed (China) Initiates Phase II/III Clinical Trials for Autoimmune Disease Drug	03-22
Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China	03-21
Hutchmed Returns to Profit in 2023; EPS Tops Estimate	02-29
EARNINGS: Hutchmed revenue surges, Craven House's loss widens	02-28
Hutchmed Swings to 2023 Profit as Revenue Increases	02-28
Hutchmed (China) Swings to Profit in FY23; Revenue Soars	02-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Other languages

Filters